High-dose therapy with melphalan followed by autologous stem cell transplant—a combination henceforth referred to as HDT/ASCT—has been the standard treatment for newly diagnosed patients with multiple myeloma (MM) for the past 20 years. Several phase 3 studies conducted before the advent of modern induction therapy with immunomodulatory drugs and proteasome inhibitors (also called “novel agents”)
1-4 confirmed that HDT/ASCT was associated with improved response rates (RR), progression-free survival (PFS), and even overall survival (OS) in some studies.
2,4 Given the unprecedented efficacy of novel agents, investigators have sought to reevaluate the role of HDT/ASCT. All prospective studies performed in the recent era have consistently shown a PFS benefit,
5-8 but their effect on RR and OS compared with the standard-dose therapy (SDT) has been variable.
5,6 Some of these discrepancies have been attributed to the use of suboptimal induction regimens, single HDT/ASCT (HDT1) vs tandem HDT/ASCT (HDT2) in the study arm, and inadequate follow-up across studies. The role of HDT2 compared withHDT1 remains unclear, especially after recent results of 2 large randomized trials that had divergent results.
9,10 Furthermore, 2 studies
7,8 that compared HDT2 with SDT showed OS benefit, but the study that compared HDT1 with SDT did not.
5 There are no randomized trials directly comparing HDT1 vs HDT2 and SDT in patients with newly diagnosed MM. Moreover, indirect comparisons of these approaches are not available as well. There is a need to clarify the relative benefits of HDT1 or HDT2 and posttransplant consolidation in the context of modern novel agent induction therapy.